Reichelt Doreen, Radad Khaled, Moldzio Rudolf, Rausch Wolf-Dieter, Reichmann Heinz, Gille Gabriele
Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt.
CNS Neurol Disord Drug Targets. 2016;15(10):1325-1332. doi: 10.2174/1871527315666160801145442.
Dopamine agonists are utilized clinically as an initial treatment in younger Parkinson's disease patients to delay the side effects associated with commencement of levodopa medication. These agonists also serveas adjunctive therapeutics with levodopa to lower the incidence of adverse motor symptoms in advanced stages of the disease.
To compare the neuroprotective effects of the dopamine agonists pergolide and pramipexole on ferrous sulfate-induced neurotoxicity in dopaminergic neurons from primary mesencephalic cell culture.
Pergolide (0.001-1 μM) and pramipexole (0.01-200 μM) were administered to 8 day primary murine mesencephalic cultures for 24 h. in the presence or absence of desferal, sulpiride or cycloheximide. Ferrous sulfate (450 μM) was then added for 24 hrs. Lactate dehydrogenase was assayed in the supernatant, glutathione concentrations measured in cell lysates and fixed cells were stained for tyrosine hydroxylase.
Ferrous sulphate induced neurotoxity in cultures (p<0.0001) was abolished in the presence of the iron chelator desferal (p<0.008). Both pergolide (p<0.0001) and pramipexole (p<0.0001) significantly protected dopaminergic neurons against ferrous sulfate induced neurotoxicity and pramipexole helped preserve neurite morphology. Pramipexole treatment significantly reduced lactate dehydrogenase release (p<0.0001) as a measure of cellular injury. The dopamine receptor antagonist sulpiride (p<0.0001) and the protein synthesis inhibitor cycloheximide (p<0.0001) reduced the neuroprotective effects of pergolide indicating the involvement receptor stimulation and de novo protein synthesis in pergolide-mediated neuroprotection. Pramipexole also significantly reversed the decrease in cellular glutathione concentrations induced by ferrous sulfate (p<0.001).
Both pergolide and pramipexole protect dopaminergic neurons against the neurotoxicity of ferrous sulfate. Pergolide specifically protects dopaminergic neurons through activation of dopamine receptors and de novo protein synthesis whereas pramipexole shows an overall effect through an antioxidant mechanism.
多巴胺激动剂在临床上被用作年轻帕金森病患者的初始治疗药物,以延缓与左旋多巴药物起始相关的副作用。这些激动剂还可作为左旋多巴的辅助治疗药物,以降低疾病晚期不良运动症状的发生率。
比较多巴胺激动剂培高利特和普拉克索对原代中脑细胞培养物中多巴胺能神经元硫酸亚铁诱导的神经毒性的神经保护作用。
将培高利特(0.001 - 1 μM)和普拉克索(0.01 - 200 μM)给予8天龄的原代小鼠中脑培养物24小时,同时存在或不存在去铁胺、舒必利或环己酰亚胺。然后加入硫酸亚铁([450 μM])24小时。检测上清液中的乳酸脱氢酶,测量细胞裂解物中的谷胱甘肽浓度,并对固定细胞进行酪氨酸羟化酶染色。
在铁螯合剂去铁胺存在的情况下,硫酸亚铁诱导的培养物中的神经毒性(p<0.0001)被消除(p<0.008)。培高利特(p<0.0001)和普拉克索(p<0.0001)均能显著保护多巴胺能神经元免受硫酸亚铁诱导的神经毒性,且普拉克索有助于保持神经突形态。普拉克索治疗显著降低了作为细胞损伤指标的乳酸脱氢酶释放(p<0.0001)。多巴胺受体拮抗剂舒必利(p<0.0001)和蛋白质合成抑制剂环己酰亚胺(p<0.0001)降低了培高利特的神经保护作用,表明受体刺激和从头蛋白质合成参与了培高利特介导的神经保护作用。普拉克索还显著逆转了硫酸亚铁诱导的细胞谷胱甘肽浓度的降低(p<0.001)。
培高利特和普拉克索均能保护多巴胺能神经元免受硫酸亚铁的神经毒性。培高利特通过激活多巴胺受体和从头蛋白质合成特异性地保护多巴胺能神经元,而普拉克索则通过抗氧化机制发挥整体作用。